Minerva Neurosciences, a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focuses on developing treatments for central nervous system diseases, including roluperidone for schizophrenia and MIN-301 for Parkinson's disease. Founded in 2014, it employs 9 people and co-developed seltorexant for insomnia and major depressive disorder.